Willow vs MedVi: Oral GLP-1 program vs compounded semaglutide

Quick verdict: Willow focuses on a structured oral GLP-1 weight management journey with progress tracking and clinician-determined treatment, while MedVi emphasizes accessible compounded semaglutide with a promotional first month at 179 and a no-clinic, online process.

Explore Willow’s program and follow-up tools

Willow vs MedVi at a glance

This comparison highlights the clearest differences between Willow and MedVi on price and promotions, medication type, support and follow-up, access model, and regulatory notes. The goal is to help you decide quickly which model aligns with your needs.

Criteria	Willow	MedVi
Starting price	299	179 first month promo; ongoing standalone month 299
Medication type	Oral GLP-1 program	Compounded semaglutide
Support and follow-up	Progress tracking tools and follow-up consultations	24/7 certified medical support and online clinician review
Access model	Telehealth-first; treatment only when licensed clinician determines appropriate	Simple online intake with no clinic visits needed
Regulatory note	Compounded medications, when offered, are not FDA-approved	Compounded medications are not FDA-approved or evaluated for safety, effectiveness or quality
Best for	Users who want structured digital follow-up	Patients who want the simplest path to compounded semaglutide

Price and promotional differences

MedVi advertises a winter promotional first month at 179 including fast, free shipping, with ongoing standalone months listed at 299 and a three-month plan at 649. Willow’s captured evidence lists a starting price of 299. If initial promotional cost is a driving factor, MedVi’s first-month promo is the distinguishing price point; if you prefer a consistent starting price shown for the program captured, Willow lists 299.

See MedVi’s promotional first-month offer

Medication type and formulation

Willow positions an oral GLP-1 program. MedVi provides clinically dosed compounded semaglutide. Both providers note compounded medication considerations in captured evidence. MedVi explicitly states it offers compounded semaglutide using active GLP-1 ingredients; Willow notes that compounded medications, when offered, are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.

Support, tracking, and clinical follow-up

Willow emphasizes a structured program designed to convert medication benefits into sustainable outcomes by combining licensed telehealth clinicians, progress tracking tools, and follow-up consultations. MedVi emphasizes a simple online intake, no clinic visits, and 24/7 support from certified medical professionals. The practical difference is Willow foregrounds behavioral scaffolding and progress tracking, while MedVi foregrounds around-the-clock access to medical support and a streamlined online experience.

Review Willow’s progress tracking and follow-up

Access model and clinician determination

MedVi’s process is fully online with no clinic visits needed; a licensed clinician reviews eligibility and prescriptions are shipped from partnered pharmacies. Willow is telehealth-first and specifies treatment is available only when a licensed clinician determines it is medically appropriate. Both use clinician review, but MedVi highlights the absence of in-person clinic visits as part of its value proposition.

Regulatory and safety notes to consider

Both providers include regulatory qualifiers about compounded medications. MedVi’s captured evidence repeatedly notes that compounded medications are not FDA-approved and are not evaluated for safety, effectiveness or quality, and encourages users to discuss risks with providers. Willow’s evidence similarly states compounded medications, when offered, are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. Treatment and prescriptions are subject to clinician review and determination at both providers.

Summary recommendation and final comparison

Willow vs MedVi: choose based on whether you prioritize structured progress tracking and a program framing around follow-up, or you prioritize a lower promotional entry price and a fully online semaglutide process with 24/7 support. Both require clinician review and note compounded medication regulatory limits.

Compare MedVi’s semaglutide program details

Choose Willow if…

You want a telehealth-first oral GLP-1 program that emphasizes licensed clinician oversight, progress tracking tools, and follow-up consultations, and you accept the program’s listed starting price of 299.

Choose MedVi if…

You want clinically dosed compounded semaglutide with a no-clinic, online intake and a promotional first month at 179 and value 24/7 certified medical support, while understanding ongoing months may be higher and compounded medications are not FDA-approved.

Primary keyword: Willow vs MedVi